28 results
8-K
EX-99.1
NKTX
Nkarta Inc
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
, which included a reduction in force of approximately 10% of its workforce, a stringent cap on future headcount, planned centralization of operations
8-K
EX-99.1
NKTX
Nkarta Inc
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
-term value creation.”
“We’ve taken the unfortunate but necessary step to streamline our workforce and reconfigure our R&D approach to be in the best
8-K
tz8vwfug4687ywa3vztv
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
EX-10.1
pjs5xn6u18
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
10-K
nu49x6eahq
25 Mar 21
Annual report
12:00am
10-Q
d2zj337
20 Aug 20
Quarterly report
4:51pm
424B4
5k7s7mdon6weaor
10 Jul 20
Prospectus supplement with pricing info
9:35pm